Metastatic melanoma patients treated with an autologous DNP-modified tumor cell vaccine develop inflammatory responses in metastatic tumors characterized by infiltration of CD8+ T cells. To further define this immune response, we analyzed T cell receptor beta-chain variable (TCRBV) region repertoire in biopsy specimens and peripheral blood lymphocytes of six patients. After administration of DNP vaccine, a restricted set of TCRBV gene families was found to be expanded compared with prevaccine metastases. In several postvaccine lesions of one patient, obtained over a 2-yr period, TCRBV14+ T cells were clonally expanded and identical T cell clonotypes could be detected. Two major recurring clones were biased toward the use of TCRBJ1S5. Furthermore, T cell lines derived from two such infiltrated skin lesions and, enriched in TCRBV14+ T cells, displayed HLA-class I-restricted lysis of the autologous melanoma cells. Clonal expansion of T cells was demonstrated in the T cell-infiltrated, postvaccine metastasis of a second patient as well. These results indicate that vaccination with autologous, DNP-modified melanoma cells can expand selected clones of T cells at the tumor site and that such clones are potentially destructive to the tumor.
M Sensi, C Farina, C Maccalli, R Lupetti, G Nicolini, A Anichini, G Parmiani, D Berd
Title and authors | Publication | Year |
---|---|---|
Portrait of an autologous cancer vaccine: Then and now.
Berd D |
Human Vaccines & Immunotherapeutics | 2023 |
T Cell Receptor Profiling in Type 1 Diabetes
LM Jacobsen, A Posgai, HR Seay, MJ Haller, TM Brusko |
Current Diabetes Reports | 2017 |
Autologous Versus Allogeneic Cell-Based Vaccines? :
G Parmiani, L Pilla, C Maccalli, V Russo |
The Cancer Journal | 2011 |
Identification of a public CDR3 motif and a biased utilization of T-cell receptor V beta and J beta chains in HLA-A2/Melan-A-specific T-cell clonotypes of melanoma patients
F Serana, A Sottini, L Caimi, B Palermo, PG Natali, P Nisticò, L Imberti |
Journal of Translational Medicine | 2009 |
Clonal expansions of 6-thioguanine resistant T lymphocytes in the blood and tumor of melanoma patients
MR Albertini, MD Macklin, CL Zuleger, MA Newton, SA Judice, RJ Albertini |
Environmental and Molecular Mutagenesis | 2008 |
Distinct Role for CD8 T Cells toward Cutaneous Tumors and Visceral Metastases
R Lengagne, S Graff-Dubois, M Garcette, L Renia, M Kato, JG Guillet, VH Engelhard, MF Avril, JP Abastado, A Prévost-Blondel |
Journal of immunology (Baltimore, Md. : 1950) | 2007 |
Vaccination: role in metastatic melanoma
L Pilla, R Valenti, A Marrari, R Patuzzo, M Santinami, G Parmiani, L Rivoltini |
Expert Review of Anticancer Therapy | 2006 |
Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia
MR Rezvany, MJ Tehrani, C Karlsson, J Lundin, H Rabbani, A Österborg, H Mellstedt |
British Journal of Haematology | 2006 |
T-cell clonotypes in cancer
PT Straten, D Schrama, MH Andersen, JC Becker |
Journal of Translational Medicine | 2004 |
T-cell receptor BV gene usage in colorectal carcinoma patients immunised with recombinant Ep-CAM protein or anti-idiotypic antibody
S Mosolits, K Markovic, J Fagerberg, JE Fr�din, MR Rezvany, S Kiaii, H Mellstedt, M Jeddi-Tehrani |
Cancer Immunology, Immunotherapy | 2004 |
Handbook of Cancer Vaccines
MA Morse, TM Clay, HK Lyerly |
2004 | |
Immunization of Patients with Malignant Melanoma with Autologous CD34+Cell-Derived Dendritic Cells TransducedEx Vivowith a Recombinant Replication-Deficient Vaccinia Vector Encoding the Human Tyrosinase Gene: A Phase I Trial
MD Nicola, C Carlo-Stella, A Anichini, R Mortarini, A Guidetti, G Tragni, F Gallino, MD Vecchio, F Ravagnani, D Morelli, P Chaplin, N Arndtz, G Sutter, I Drexler, G Parmiani, N Cascinelli, AM Gianni |
Human Gene Therapy | 2003 |
Immunotherapy of Cancer by Active Vaccination: Does Allogeneic Bone Marrow Transplantation after Non-Myeloablative Conditioning Provide a New Option?
M Zöller |
Technology in cancer research & treatment | 2003 |
Leukemia-associated monoclonal and oligoclonal TCR-BV use in patients with B-cell chronic lymphocytic leukemia
MR Rezvany, M Jeddi-Tehrani, H Wigzell, A Österborg, H Mellstedt |
Blood | 2003 |
Synthetic and natural non-live vectors: rationale for their clinical development in cancer vaccine protocols
E Tartour, F Benchetrit, N Haicheur, O Adotevi, WH Fridman |
Vaccine | 2002 |
M-Vax: an autologous, hapten-modified vaccine for human cancer
D Berd |
Expert Opinion on Biological Therapy | 2002 |
Cancer Immunotherapy With Peptide-Based Vaccines: What Have We Achieved? Where Are We Going?
G Parmiani, C Castelli, P Dalerba, R Mortarini, L Rivoltini, FM Marincola, A Anichini |
JNCI Journal of the National Cancer Institute | 2002 |
Improved Assessment of T-Cell Receptor (TCR) VB Repertoire in Clinical Specimens: Combination of TCR-CDR3 Spectratyping with Flow Cytometry-Based TCR VB Frequency Analysis
H Pilch, H Hohn, K Freitag, C Neukirch, A Necker, P Haddad, B Tanner, PG Knapstein, MJ Maeurer |
Clinical and vaccine immunology : CVI | 2002 |
Comparative assessment of TCRBV diversity in T lymphocytes present in blood, metastatic lesions and DTH sites of two melanoma patients vaccinated with an IL-7 gene-modified autologous tumor cell vaccine
M Carsana, G Tragni, G Nicolini, I Bersani, G Parmiani, A Anichini, YS Sun, P Möller, D Schadendorf, ML Sensi |
Cancer Gene Therapy | 2002 |
TCR Rearrangement in Lymphocytes Infiltrating Melanoma Metastases After Administration of Autologous Dinitrophenyl-Modified Vaccine
J Manne, MJ Mastrangelo, T Sato, D Berd |
Journal of immunology (Baltimore, Md. : 1950) | 2002 |
Specific Immunotherapy of Cancer in Elderly Patients
S Matzku, M Z??ller |
Drugs & Aging | 2001 |
Autologous, hapten-modified vaccine as a treatment for human cancers
D Berd |
Vaccine | 2001 |
Tumour Cell-Based Vaccines for the Treatment of Melanoma:
EC Hsueh |
BioDrugs | 2001 |
Specific Immunotherapy of Cancer in Elderly Patients:
S Matzku, M Zller |
Drugs & Aging | 2001 |
Monitoring of antigen-specific cytolytic T lymphocytes in cancer patients receiving immunotherapy
TL Whiteside |
Clinical and diagnostic laboratory immunology | 2000 |
Vaccination of Melanoma Patients with an Allogeneic, Genetically Modified Interleukin 2-Producing Melanoma Cell Line
S Osanto, PP Schiphorst, NI Weijl, N Dijkstra, AV Wees, N Brouwenstein, N Vaessen, JH Krieken, J Hermans, FJ Cleton, PI Schrier |
Human Gene Therapy | 2000 |
Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma
D Schadendorf, A Paschen, Y Sun |
Immunology Letters | 2000 |
Development of non-live vectors and procedures (liposomes, pseudo-viral particles, toxin, beads, adjuvants…) as tools for cancer vaccines
E Tartour, A Ciree, N Haicheur, F Benchetrit, WH Fridman |
Immunology Letters | 2000 |
Advances in specific immunotherapy of malignant melanoma
C Curiel-Lewandrowski, MF Demierre |
Journal of the American Academy of Dermatology | 2000 |
Tumor-specific immunotherapy based on dominant models of natural tolerance
E Montero, JF Amador, R Pérez, A Lage |
Medical Hypotheses | 2000 |
Letters to the Editor: 2
R Strohal, G Stingl |
Journal of Investigative Dermatology | 1999 |
In vivo selective expansion of a tumour-specific cytotoxic T-cell clone derived from peripheral blood of a melanoma patient after vaccination with gene-modified autologous tumour cells
Y Sun, P Möller, C Berking, EM Schlüpen, M Volkenandt, D Schadendorf |
Immunology | 1999 |
T cell receptor usage in malignant diseases
E Halapil, M Jeddi-Tehrani, A sterborg, H Mellstedt |
Springer Seminars in Immunopathology | 1999 |
Characterization of a novel subset of CD8(+) T cells that expands in patients receiving interleukin-12
JA Gollob, CP Schnipper, E Orsini, E Murphy, JF Daley, SB Lazo, DA Frank, D Neuberg, J Ritz |
Journal of Clinical Investigation | 1998 |
First Comparative Delineation of the T Cell Receptor Repertoire in Primary and Multiple Subsequent/Coexisting Metastatic Melanoma Sites
R Strohal, C Brna, U Mossbacher, G Fischer, H Pehamberger, G Stingl |
Journal of Investigative Dermatology | 1998 |
Oligoclonal T cells in human cancer
E Halapi |
Medical Oncology | 1998 |
Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma
R Soiffer, T Lynch, M Mihm, K Jung, C Rhuda, JC Schmollinger, FS Hodi, L Liebster, P Lam, S Mentzer, S Singer, KK Tanabe, AB Cosimi, R Duda, A Sober, A Bhan, J Daley, D Neuberg, G Parry, J Rokovich, L Richards, J Drayer, A Berns, S Clift, LK Cohen, RC Mulligan, G Dranoff |
Proceedings of the National Academy of Sciences | 1998 |
A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire
FM Batliwalla, BA Bateman, D Serrano, D Murray, S Macphail, VC Maino, JC Ansel, PK Gregersen, CA Armstrong |
Molecular Medicine | 1998 |
Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy
P Romero, JC Cerottini, GA Waanders |
Molecular Medicine Today | 1998 |
Future perspectives in specific immunotherapy of melanoma
G Parmiani |
European Journal of Cancer | 1998 |
Dinitrophenyl-Modified Autologous Melanoma Vaccine Induces a T Cell Response to Hapten-Modified, Melanoma Peptides
T Sato, TN Bullock, LC Eisenlohr, MJ Mastrangelo, D Berd |
Clinical Immunology and Immunopathology | 1997 |
Vaccine Trials for the Clinician: Prospects for Tumor Antigens
S Osanto |
The oncologist | 1997 |